Leadership Team

Sam Lanyon

Executive Chair and Interim CEO

Sam Lanyon has more than 25 years of experience in strategy, sales and operations with a demonstrated track record in the global commercialization of technology rich healthcare products. Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and a Non-Executive Director of Paragon Funds Management. He also serves as a Non-Executive Director of Visus Therapeutics, a clinical-stage company focused on developing innovation medicines to improve vision. Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation, and ASX listed Vision Systems Ltd where he was responsible for establishing Vision Biosystem’s sales, marketing, and service operations throughout the EU, Middle East, Latin America, and Asia Pacific.

Mr. Lanyon holds an Honours degree in Mechanical Engineering from the University of Melbourne, a Post Graduate Diploma in Management from Melbourne Business School and has completed strategy training from London Business School.

Rob Sambursky, MD

President and Chief Medical Officer

Rob Sambursky, MD has more than 25 years of biotech and clinical experience. Dr. Sambursky joined Lumos Diagnostics in 2019 when RPS Diagnostics, a company he co-founded, merged with Lumos. He serves as the President and Chief Medical Officer for Lumos and he also serves on the Board of Directors for PPK Solutions and Visus Therapeutics, Inc.

Dr. Sambursky has strong scientific and clinical background in medical sciences, ophthalmology and infectious disease. He has authored numerous patents and scientific papers, conceived a novel point-of-care (POC) diagnostic test platform, served as the clinical and regulatory interface that led to multiple POC diagnostic tests obtaining international regulatory clearances as well as U.S. FDA 510(k) clearances with CLIA waiver designations. In parallel, he successfully built teams that commercialized multiple diagnostic tests in the U.S. and abroad.

Dr. Sambursky is a board-certified ophthalmologist with fellowship training in refractive surgery and corneal external and infectious disease. He earned a BA in Biology from Brown University, an MA in Medical Sciences with concentrations in biochemistry and microbiology from Boston University and an MD from Boston University School of Medicine. Dr. Sambursky completed his internal medicine internship at Harvard’s Mount Auburn Hospital and both his ophthalmology residency and cornea fellowship at Wills Eye Hospital in Philadelphia.

Sacha Dopheide, PhD

Chief Technology Officer

Sacha Dopheide, PhD has more than 15 years of experience in the in vitro diagnostic device industry, ranging from point-of-care devices to laboratory analyzers. She currently serves as the company’s Chief Technology Officer and has held an executive leadership role within Lumos Diagnostics since its acquisition of Kestrel Bioscience in 2017. Dr. Dopheide has experience managing the full range of product development for both immunoassays and their accompanying electronic readers from proof of concept through development, verification and external validation trials. Dr. Dopheide has taken a leading role in identification and due diligence of M&A targets and integration activities. She also leads the Lumos Diagnostic service business unit’s business development activities, including directly conducting global market research, establishing partnerships and generating strategic product roadmaps for new tests.

Dr. Dopheide holds a BSc with First Class Honours in Biochemistry and Molecular Biology from Monash University. She received her PhD in Medicine in 2000, for which she was awarded the Victoria Fellowship for Excellence in Medical Research.

Barrie Lambert

Chief Financial Officer

Barrie Lambert has more than 20 years of international experience in high growth companies from the medical device research and development services and manufacturing sector, as well as technology, retail, ecommerce, consumer goods and business services. Prior to joining Lumos Diagnostics, Mr. Lambert was the Chief Financial Officer of Planet Innovation, one of the founding shareholders and current major shareholder of Lumos. In that role, he was a member of the executive team helping to grow Planet Innovation fourfold, completing several capital raises, financing, and merger and acquisition transactions.

Mr. Lambert’s previous roles have included Chief Financial Officer and President & Chief Executive Officer of technology businesses with operations in Australia, United States, New Zealand and United Kingdom. He also spent more than six years as Chief Financial Officer, Vice President of Operations, then as the Vice President and General Manager of Sephora.com, a business unit of Louis Vuitton Moet Hennessy.

Mr. Lambert has a broad background in governance, strategy, finance, M&A, operations, technology and sales, which have allowed him to drive positive change by partnering with the Executive Team and Board of Directors to set and execute strategy, deliver quality customer service and create value. His qualifications include a BA in Accounting from the University of South Australia, Chartered Accountant from the Australian Institute of Chartered Accountants, MBA from the Graduate School of Business, University of Sydney, and a graduate of the Australian Institute of Company Directors.

Jill Thompson

Senior Vice President of Corporate Strategy and Development

Jill Thompson has more than 25 years of experience in the life science and diagnostics industry. She currently serves as the company’s Senior Vice President of Corporate Strategy and Development.

Prior to joining Lumos Diagnostics, Ms. Thompson most recently served as President and Practice Leader for the JoLT Group where she provided management and consulting services to individuals and companies in all stages of business development. She is renowned for leading turnarounds, business development strategies, product development and commercialization projects, mergers and acquisitions, sales and distribution initiatives, licensing, joint ventures, market research, and implementing complex enterprise integrations.

She also served as Senior Vice President of Business Development at Orasure Technologies where she extricated the company from litigious situations, sourced rare reagents, and negotiated agreements that led to the rapid point-of-care Ebola test that was launched in Africa.

For more than 10 years, Ms. Thompson was Vice President of Business Development for Alere where she closed more than 15 deals ranging in value from $2M to over $100M. In this role, she transitioned accounts through multiple acquisitions, moved a $100M manufacturing business to China, and was pivotal in developing and launching three new diagnostic testing devices to expand the company’s product portfolio.

Ms. Thompson earned a BS in Psychology at Texas A&M University in College Station, TX.

Sarah Glubka

Senior Director of Human Resources

Sarah Glubka has more than 17 years of experience in human resources and currently serves as the company’s Senior Director of Human Resources.

Ms. Glubka most recently served as the Director of Human Resources for Australia-based Planet Innovation where she developed business initiatives, fostered employee engagement and mobilized talent. She was a key strategic business partner for the global product and service organization; working collaboratively with the leadership team and board of directors to establish strategies to ensure staff engagement. Ms. Glubka also championed, designed and implemented a successful company-wide employee health and safety program. Prior to Planet Innovation, Ms. Glubka was the Supervisor of Administrative Services for Kaiser Permanente where she developed payroll and attendance reports, metrics and analytics to support business needs and increase efficiencies. She also has expertise establishing human resource infrastructures for U.S. entities, including policies, standardized processes and procedures, and documentation to ensure compliance with all state and federal regulations as well as provide consistency in practice across the company.  

Ms. Glubka earned a BS in Business Management from the University of Phoenix.

Annie Bell

Senior Director of Medical Affairs

Annie Bell has more than 15 years of professional experience in the medical device and in vitro diagnostic industry including direct patient management, medical education and clinical study management. Currently serving as the Director of Medical Affairs for Lumos Diagnostics, Ms. Bell is a strategic leader with a passion for improving patient lives through early detection of disease. She has expertise in the initiation and oversight of clinical trials including FDA registration trials.

Ms. Bell holds a BS in Nursing from Pennsylvania State University, an MS in Nursing from Rush University Chicago, IL, and is a graduate of the Global Clinical Trials Clinical Research Program, Harvard Medical School, Boston MA. In addition, Ms. Bell is a Board-certified Neonatal Nurse Practitioner.

Sue Hibbeln

Senior Director of Regulatory Affairs

Sue Hibbeln has more than 15 years in Regulatory Affairs and Quality Assurance at start-up, mid- and large-sized companies for a variety of medical devices, including in vitro diagnostic devices, software, hardware, implants and sutures. She currently serves as the company’s Senior Director of Regulatory Affairs. Ms. Hibbeln specializes in global strategy, registration, regulatory/cultural intelligence and quality systems.

Her passion for working with diverse cultures has enabled opportunities to work with world-class talent on global cross-functional teams. Ms. Hibbeln especially enjoys helping clients with global remediation and harmonization efforts and monitors direction from the International Medical Device Regulators Forum (IMDRF). Ms. Hibbeln is a CMMI Associate and a certified appraisal team member (ATM) for the Medical Device Discovery Appraisal Program (MDDAP) – a joint initiative for FDA, MDIC, and CMMI.

Ms. Hibbeln earned a BA from LaSalle University, an MS in Regulatory Affairs from San Diego State University and a Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professionals Society (RAPS). She also completed the Kellogg Executive Leadership Program at Northwestern University.